on November 17, 2020 Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, reported that management will host an investor conference call to discuss AUTO1 and AUTO3 data presented at the American Society of Hematology (ASH) (Free ASH Whitepaper) Virtual Congress 2020 and will also participate in the Jefferies Banking Conference (Press release, Autolus, NOV 17, 2020, View Source [SID1234571272]):
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
19 November 2020 – Dr. Christian Itin, chairman and chief executive officer, will participate in an analyst led fireside chat and host virtual one-on-one meetings at the Jefferies Virtual London Healthcare Conference at 11.25 am ET, 4.25 pm GMT. A live audio webcast of the fireside chat will be available on the investor relations section of the Company’s website at Autolus. An archived replay will be available for a period of 30 days after the conference.
7 December 2020 – Dr. Christian Itin, chairman and chief executive officer, along with the Autolus clinical team, will host an investor call and webcast at 4.00 pm ET, 9.00 pm GMT to discuss presentations related to its AUTO1 and AUTO3 programs, the company’s CAR T cell therapies being investigated in adult Acute Lymphoblastic Leukemia (ALL) and relapsed/ refractory diffuse large B cell lymphoma (DLBCL), respectively, during the ASH (Free ASH Whitepaper) conference. To listen to the webcast and view the accompanying slide presentation, please go to Autolus. After the conference call, a replay will be available for a period of one week.